Quantcast

Latest Angiotech Pharmaceuticals Inc. Stories

2009-10-23 08:00:00

VANCOUVER, Oct. 23 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), today announced the commercial launch of the Tan EndoGlide(TM) Endothelium Insertion System in the United States. Angiotech holds exclusive U.S. distribution rights to market and distribute the Tan EndoGlide Endothelium Insertion System, which it obtained in a supply agreement with privately held Network Medical Products, Ltd. Angiotech will launch the product during the American Academy of...

2009-10-09 11:35:00

Third Quarter 2009 Financial Results VANCOUVER, Oct. 9 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) will host a conference call discussing its financial results for the third quarter ended September 30, 2009, on Monday November 9, 2009 at 11:00 AM ET (8:00 AM Pacific). Dial-in information for the earnings call on November 9, 2009 is as follows: North America (toll-free): 800.599.9829 International: 617.847.8703 Enter Passcode:...

2009-09-14 11:29:00

HAE:TSX MONTREAL, Sept. 14 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE) reported today on current activities and released the financial results of its third quarter ended July 31. Current Activities Haemacure and Angiotech Pharmaceuticals, Inc. started work pursuant to the strategic collaboration entered into in June 2009, including the shipment of product to Angiotech. This collaboration provides Angiotech with license, distribution and supply rights for Haemacure's...

2009-08-20 07:30:00

VANCOUVER, Aug. 20 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI; TSX: ANP), today announced the commercial launch of the Option(TM) Inferior Vena Cava (IVC) Filter in the United States, following FDA 510(k) clearance in June and a limited pre-launch in July. Angiotech holds exclusive worldwide rights to market and distribute the Option IVC Filter, which it obtained in a license agreement with privately held Rex Medical, LP (Rex Medical), as announced in March 2008....

2009-08-11 07:00:00

The World's First Peripheral Drug-Eluting Stent Now Available in Europe VANCOUVER, Aug. 11 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced Cook Medical, a license holder of Angiotech's paclitaxel technology, reported CE Mark approval and limited commercial launch of the Zilver(R) PTX(R) Drug-Eluting Peripheral Stent in Europe. This approval represents a global landmark in bringing drug-eluting stent (DES) technology to people suffering from...

2009-08-06 07:30:00

VANCOUVER, Aug. 6 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced its financial results for the second quarter ended June 30, 2009. "We were pleased to observe continued sales growth in our Proprietary Medical Products business during the quarter, including continued acceleration of our important Quill(TM) SRS and HemoStream(TM) product lines," said Dr. William Hunter, President and CEO of Angiotech. "Despite the continued challenges we are...

2009-08-04 07:30:00

VANCOUVER, Aug. 4 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced the launch of a series of new, proprietary Quill(TM) SRS product codes specifically designed for laparoscopic, or minimally invasive, gynecology procedures, including hysterectomies and myomectomies. In 2008, there were approximately 750,000 hysterectomies performed in the United States of which approximately 130,000 were performed laparoscopically. In addition, there were...

2009-07-23 15:58:00

VANCOUVER, July 23 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today filed a preliminary short form base shelf prospectus with the securities commissions of British Columbia and Ontario and a corresponding shelf registration statement on Form S-3 with the United States Securities and Exchange Commission (collectively, the "Offering Documents"). The Offering Documents, when made final and / or declared effective, will allow Angiotech to make offerings of...

2009-07-16 11:51:00

VANCOUVER, July 16 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX) has received approval from the U.S. Food and Drug Administration (FDA) to market its TAXUS(R) Liberte(R) Long Paclitaxel-Eluting Coronary Stent System, a next-generation drug-eluting stent (DES) designed for long lesions. At 38 mm, it is the longest available DES, providing doctors an option that can...

2009-06-11 06:00:00

HAE:TSX MONTREAL, June 11 /PRNewswire-FirstCall/ - Haemacure Corporation (TSX : HAE) released today the results of its second quarter ended April 30, and reports on its recently concluded strategic collaboration with Angiotech Pharmaceuticals, Inc. Stategic Collaboration As previously announced on June 3, 2009, Angiotech Pharmaceuticals, Inc. and Haemacure have entered into a strategic collaboration which provides Angiotech with license, distribution and supply rights related to...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related